(Q29620917)

English

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

scientific article (publication date: October 2014)

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25240821

30 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

10

object named as

Tae-You Kim

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

20

object named as

Atsushi Ohtsu

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Hansjochen Wilke

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Kei Muro

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Eric Van Cutsem

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Sang-Cheul Oh

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

György Bodoky

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Yasuhiro Shimada

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Shuichi Hironaka

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Naotoshi Sugimoto

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Oleg Lipatov

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Philippe Rougier

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Yoshito Komatsu

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Michael Emig

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Roberto Carlesi

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

David Ferry

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Kumari Chandrawansa

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Jonathan D Schwartz

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

RAINBOW Study Group

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25240821

30 April 2017

publication date

17 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Lancet Oncology Commission

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25240821

30 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

15

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25240821

30 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

11

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25240821

30 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1224-1235

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Modeling valuations for EuroQol health states

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970420-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70420-6

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25240821

30 April 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25240821

30 April 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240821%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29620917&oldid=1777453262"